OOIR: Observatory of International Research

Papers

(The median citation count of JACC: Cardiooncology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Full Issue PDF	135
Priorities in Cardio-Oncology	132
Balancing Promise and Evidence	115
Hormonal Therapy and Cardiovascular Health	102
Full Issue PDF	94
Epigenomics of Cardio-Oncology	81
Atrial Fibrillation in Patients With Cancer	76
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	76
Full Issue PDF	72
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	66
Editorial Board	65
Cardiovascular Safety in Oncology Clinical Trials	61
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	61
Behaviorally Designed Gamification and Physical Activity Among Breast and Prostate Cancer Survivors	60
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	59
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	56
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	56
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors	55
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD	51
Full Issue PDF	51
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms	48
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis	45
Frailty	42
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA	42
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	41

Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	40
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	39
Cardiac Risk Stratification Before Lung Cancer Radiation	39
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy	36
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)	36
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD	33
Peripheral Ischemia Fuels Breast Cancer Via Myeloid-Skewed Hematopoiesis	33
Editorial Board/Officers Page	33
Clonal Hematopoiesis in Cancer and Cardiovascular Disease	32
Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer	32
Permissive Cardiotoxicity	31
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance	29
Cancer Immunotherapy Beyond Checkpoint Blockade	28
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients	27
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors	27
PROPORTIONATE AND ABSOLUTE PULMONARY EMBOLISM MORTALITY IN ONCOLOGY IN THE UNITED STATES FROM 1999-2019	27
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation	26
Leveling Up	26
Full Issue PDF	26
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy	26
TRASTUZUMAB CARDIOTOXICITY IN EARLY STAGE HER2 POSITIVE BREAST CANCER PATIENTS IN MEXICO	25
Editorial Board	25
SUCCESSFUL DIAGNOSIS AND SURGICAL RESECTION OF A PULMONIC SARCOMATOID CARCINOMA LACKING PET AVIDITY OR MALIGNANT APPEARING CMR TISSUE CHARACTERISTICS	25
Developing a Model for Cross-Institutional Educational Collaborations	25
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research	24
Reply	24
Endothelin-1	24
Quality-of-Care Measures for Cardio-Oncology	23
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity	23
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity	23
Vascular Complications of Atrial Fibrillation in Patients With Cancer	22
A CHALLENGING CASE OF A LARGE RIGHT HEART MASS COMPLICATED BY COMPLETE HEART BLOCK	22
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge	22
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity	22
CHA2DS2-VASc Score in Cardio-Oncology	22
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy	22
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction	22
Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer	22
Fluoropyrimidine Therapy in Gastrointestinal Cancer	21
Full Issue PDF	21
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients	21
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity	21
Diet and Prevention of Cardiovascular Disease and Cancer	20
High-Sensitivity Troponin I	19
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.	18
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy	18
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction	18
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer	18
Low QRS Voltages in Cardiac Amyloidosis	18
Imaging Immune Checkpoint Inhibitor Myocarditis	18

The United Kingdom’s First Cardio-Oncology Service	18
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction	18
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia	17
FULL ISSUE PDF	17
Cardiovascular Risk Assessment in Patients With Kidney Cancer	17
To Adjudicate or Not Adjudicate	17
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity	17
Cancer Therapy–Related Cardiac Dysfunction	16
ABSTRACT WITHDRAWN	15
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors	15
Full Issue PDF	15
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer	15
SEX DIFFERENCES IN ANTHRACYCLINE-TREATED CANCER SURVIVORS ASSESSED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING	15
Author Index	15
Hearts on the Minds of Oncologists	15
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy	14
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?	14
Full Issue PDF	14
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors	14
Navigating the Uncharted	13
Cardiovascular Considerations After Cancer Therapy	13
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors	13
Cardiovascular Care After Cancer	13
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness	13
(Less) Time and Energy	13
Guiding Treatment With Recovered CTRCD	13
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?	13
Preventing Cancer Therapy–Related Cardiotoxicity	12
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction	12
Reply	12
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	11
Reply	11
PALLIATIVE RESECTION OF A CARDIAC SARCOMA	11
Addressing the Overlooked	11
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	11
JACC: CardioOncology	11
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY	11
Reply	11
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	11
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT	11
Clinical Practice Guidelines in Cardio-Oncology	11
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	11
Reply	10
Editorial Board/Officers Page	10
Overcoming LGBTQI+ Disparities in Cardio-Oncology	10
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy	10
The Cause of Death in Patients With Cancer	10
Full Issue PDF	10
TYROSINE KINASE INHIBITOR ASSOCIATED POLYMORPHIC VENTRICULAR TACHYCARDIA	10
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy	10
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	10
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	10
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB	10
ASYMPTOMATIC CARDIAC METASTASIS OF NEUROENDOCRINE TUMOR DIAGNOSED BY PET CT SCAN	10
Reply	9
The ESC Cardio-Oncology Guidelines	9
Full Issue PDF	9
Learning From Trials	9
When Clot Is Tumor	9
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology	9
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors	9
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation	9
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	9
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients	8
Reply	8
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors	8
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity	8
Reply	8
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma	8
Editorial Board	8
Longitudinal Patterns of Cardiovascular Disease and Cancer Mortality in Renal Cell Carcinoma Patients by Tumor Stage	8
Assessing STEMI Outcomes in Patients With Cancer	8
FIRST DOSE ORTHOSTATIC HYPOTENSION FOLLOWING DOCETAXEL AND GEMCITABINE INFUSION	8
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category	8
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients	8
Cancer Diagnosis, Physical Activity, and Heart Disease Risk	8
Reply	8
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy	8
Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer	8
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice	8

Sarcoma: Cardiovascular and Oncologic Considerations	7
MARANTIC ENDOCARDITIS - DIAGNOSTIC AND MANAGEMENT CHALLENGES	7
Physical Inactivity, Adverse Body Composition, and Cardiac Function in Breast Cancer Survivors	7
Longitudinal Right Ventricular Systolic Function Changes in Breast Cancer Patients Treated With Cardiotoxic Cancer Therapy	7
Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes	7
Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors	7
Ablating Late Cardiovascular Events in Modern Hematopoietic Cell Transplantation	7
Pumping Up the Standards	7
Leukemia and Heart Disease	7
Blood Pressure Lowering and Risk of Cancer	7
Shared Mechanisms in Cancer and Cardiovascular Disease: S100A8/9 and the NLRP3 Inflammasome	7
Full Issue PDF	7
Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy	7
Recognizing and Responding to Cardiac Risk With Osimertinib	7
Melanoma Treatment	7
Immune Checkpoint Inhibitor Myocarditis and Cellular Rejection in Orthotopic Heart Transplant Recipients	7
Reply	6
Incident Cancer in Heart Failure Patients and the Need for Additional Investigations	6
Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT	6
Risk of Incident Heart Failure Among Young Adult Cancer Survivors	6
New Cardiotoxicity Risk Assessment Guidelines	6
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors	6
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis	6
Assessing the Certainty of Evidence on Efficacy and Safety of Anticoagulants for Cancer-Associated Thrombosis	6
Mediterranean Diet Is Associated With Lower All-Cause and Cardiovascular Mortality Among Long-Term Cancer Survivors	6
Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis	6
The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer	6
Modifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer	6
Reduced Thoracic Aortic Distensibility Upon Breast Cancer Diagnosis (WF-97415 and WF-98213)	6
Editorial Board	6
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis	6
Mitigation of Doxorubicin Cardiotoxicity With Synergistic miRNA Combinations Identified Using Combinatorial Genetics en masse (CombiGEM)	6
AL Amyloidosis for Cardiologists	6
Articulating the JACC Journals’ Direction in Times of Global Change	5
SARCOIDOSIS MIMICKING CARDIAC AMYLOIDOSIS: A CHALLENGING CONUNDRUM	5
More Data to Support a Cardiac-Oncologic Partnership	5
Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults	5
Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib	5
Exercise Training in Breast Cancer Survivors	5
Reply	5
Potential and Pitfalls of Pharmacovigilance Databases in Oncology	5
Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies	5
Cancer-Associated Venous Thromboembolism	5
Troponin Surveillance in Patients Receiving Immune Checkpoint Inhibitors	5
Significance of Alectinib-Induced Bradycardia	5
Determinants of Impaired Peak Oxygen Uptake in Breast Cancer Survivors: JACC: CardioOncology Primer	5
Personalized Trastuzumab-Induced Cardiac Dysfunction Risk Stratification and Surveillance	5
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions	4
Full Issue PDF	4
Arterial Thromboembolism in Patients With AF and CHA2DS2-VASc Score 0-2 With and Without Cancer	4
Cardiovascular Disease in Myeloproliferative Neoplasms	4
Epidemiology and Antithrombotic Therapy for Cancer-Associated Arterial Thromboembolism in Japan	4
Embracing the Power of the Polysocial Risk Score	4
Imaging-Based Obesity Assessment for Risk Factor Stratification and Prognostication in Malignancy	4
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity	4
Editorial Board	4
ER-Specific Autophagy or ER-Phagy in Cardiac Myocytes Protects the Heart Against Doxorubicin-Induced Cardiotoxicity	4
Steroids in Immune Checkpoint Inhibitor Myocarditis	4
Editorial Board/ACC Officers Page	4
Is Preventative Oophorectomy Safe?	4
Predictors of Atrial Fibrillation After Thoracic Radiotherapy	4
Health Literacy, Individual and Community Engagement, and Cardiovascular Risks and Disparities	4
Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors	4
Editorial Board/Officers Page	4
Risk of Hematologic Malignancies in Patients With Acute Myocardial Infarction	4
Haptoglobin Gene Expression and Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors	4
Reply	4
Probing the Anthracycline-Induced Myocardial Injury	4
How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer	4
Cardio-Oncology and Health Equity	4
Walk Your Way Out of Cardiovascular Risk	3
Echocardiography-Guided Radiofrequency Ablation for Cardiac Tumors	3
Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort	3
Longitudinal Strain and Troponin I Elevation in Patients Undergoing Immune Checkpoint Inhibitor Therapy	3
Editorial Board	3
Full Issue PDF	3
Raise the Flag	3
Outcomes and Predictors of Severity of Immunotherapy-Related Myocarditis	3
SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunction	3
CARDIOVASCULAR DISEASE RISK CONTROL IN SURVIVORSHIP: THE ROLE AND IMPLEMENTATION OF CARDIO-ONCOLOGY SERVICES	3
Diversity in Cardio-Oncology Clinical Trials	3
Cancer and Cardiovascular Disease	3
Understanding Race, Genotype, and Socioeconomic Status in Transthyretin Amyloid Cardiomyopathy	3
Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer	3
How Common Is Pre-Existing Cardiovascular Disease in Cancer Patients	3
Risk of Heart Failure Hospitalization in Patients Treated With Osimertinib	3
The FLC Ratio Reframed	3
Cardio-Oncology Care Delivery for All Patients With Cancer Within Academic and Community Settings	3
The Potential Impact of the 2022 ESC Cardio-Oncology Guidelines on Clinical Practice in China	3
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies	3
Synergistic miRNA Combinations Mitigate Doxorubicin-Induced Cardiotoxicity	3
Immune Checkpoint Inhibitors in Cardiac Sarcoma	3
Full Issue PDF	3
Effects of Aerobic Exercise on Cardiorespiratory Fitness and Cardiovascular Risk Factors in Long-Term Breast Cancer Survivors	3
Tight Regulation of Erk Activity Protects From Anthracycline-Induced Cardiotoxicity	3